Skip to main content

Advertisement

Table 2 Acute and late adverse events in the NACT + RT and CCRT groups

From: Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis

Adverse event NACT + RT group [cases (%)] CCRT group [cases (%)] P value
Grade 1–4 Grade 3–4 Grade 1–4 Grade 3–4
Neoadjuvant phase
 Neutropenia 61 (62.2) 24 (24.5) NA NA NA
 Leukopenia 54 (55.1) 20 (20.4) NA NA NA
 Thrombocytopenia 11 (11.2) 4 (4.1) NA NA NA
 Nausea/vomiting 47 (48.0) 6 (6.1) NA NA NA
 Hepatotoxicity 53 (54.1) 3 (3.1) NA NA NA
 Nephrotoxicity 37 (37.8) 1 (1.0) NA NA NA
Irradiation phase
 Mucositis 98 (100) 40 (40.8) 116 (100) 67 (57.8) 0.028
 Xerostomia 98 (100) 24 (24.5) 116 (100) 35 (30.2) 0.439
 Skin 98 (100) 11 (11.2) 116 (100) 19 (16.4) 0.376
 Nausea/vomiting 41 (41.8) 7 (7.1) 68 (58.6) 10 (8.6) 0.885
 Leukopenia 43 (43.9) 15 (15.3) 71 (61.2) 35 (30.2) 0.016
 Neutropenia 36 (36.7) 11 (11.2) 75 (64.7) 30 (25.9) 0.011
 Thrombocytopenia 15 (15.3) 3 (3.1) 24 (20.7) 7 (6.0) 0.157
 Hepatotoxicity 28 (28.6) 1 (1.0) 40 (34.5) 2 (1.7) 0.864
 Nephrotoxicity 22 (22.4) 0 (0) 32 (27.6) 0 (0) 0.789
Post-irradiation phase
 Xerostomia 98 (100) 10 (10.2) 116 (100) 25 (21.6) 0.041
 Hearing loss 34 (34.7) 6 (6.1) 69 (59.5) 20 (17.2) 0.023
 Neuropathy 24 (24.5) 2 (2.0) 37 (31.9) 1 (0.9) 0.761
 Neck tissue damage 9 (9.2) 0 (0) 15 (12.9) 0 (0) 0.867
 Dysphagia 1 (1.0) 0 (0) 2 (1.7) 0 (0) 0.998
  1. Comparison of the incidence of grade 3–4 events between the two groups
  2. NA not applicable
  3. P values were calculated using a Chi square test